This brand name is authorized in Brazil, Estonia, Lithuania
The drug OLYSIO contains one active pharmaceutical ingredient (API):
|
1
Simeprevir
UNII 16U7H60184 - SIMEPREVIR SODIUM
|
|
Simeprevir is a specific inhibitor of the hepatitis C virus (HCV) NS3/4A serine protease, which is essential for viral replication. In a biochemical assay, simeprevir inhibited the proteolytic activity of recombinant genotype 1a and 1b HCV NS3/4A proteases, with median Ki values of 0.5 nM and 1.4 nM, respectively. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| J05AP05 | J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AP Antivirals for treatment of HCV infections | |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: BR | Câmara de Regulação do Mercado de Medicamentos | Identifier(s): 514515040027602 |
| Country: EE | Ravimiamet | Identifier(s): 1647626, 1647637 |
| Country: LT | Valstybinė vaistų kontrolės tarnyba | Identifier(s): 1073392, 1073393 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
